CN118354770A - 具有gabaa受体活性的类黄酮衍生物及使用方法 - Google Patents
具有gabaa受体活性的类黄酮衍生物及使用方法 Download PDFInfo
- Publication number
- CN118354770A CN118354770A CN202280080629.4A CN202280080629A CN118354770A CN 118354770 A CN118354770 A CN 118354770A CN 202280080629 A CN202280080629 A CN 202280080629A CN 118354770 A CN118354770 A CN 118354770A
- Authority
- CN
- China
- Prior art keywords
- compound
- bond
- independently
- group
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
- C07D265/22—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163253341P | 2021-10-07 | 2021-10-07 | |
| US63/253,341 | 2021-10-07 | ||
| PCT/US2022/045904 WO2023059802A1 (en) | 2021-10-07 | 2022-10-06 | Flavonoid derivatives with gabaa receptor activity and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118354770A true CN118354770A (zh) | 2024-07-16 |
Family
ID=85803715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280080629.4A Pending CN118354770A (zh) | 2021-10-07 | 2022-10-06 | 具有gabaa受体活性的类黄酮衍生物及使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240398821A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4412605A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024538721A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118354770A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022361421A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3233822A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023059802A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS604831B2 (ja) * | 1975-10-20 | 1985-02-06 | 中外製薬株式会社 | 4(3h)−キナゾリノン誘導体の製法 |
| US5258478A (en) * | 1992-04-27 | 1993-11-02 | Florida State University | Low self-absorbing, intrinsically scintillating polymers |
| GB9521184D0 (en) * | 1995-10-17 | 1995-12-20 | Univ Strathclyde | Flavonoids |
| RU2214405C2 (ru) * | 1998-02-18 | 2003-10-20 | НьюроСёрч А/С | Новые соединения и их применение в качестве положительных модуляторов амра-рецепторов |
| AU5261001A (en) * | 2000-04-27 | 2001-11-12 | Imperial Cancer Research Technology Ltd | Condensed heteroaryl derivatives |
| US7846915B2 (en) * | 2004-10-20 | 2010-12-07 | Resverlogix Corporation | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| CA2808680A1 (en) * | 2010-08-24 | 2012-03-01 | The Regents Of The University Of California | Methods of treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprise the administration of dihydromyricetin |
| CN106478525A (zh) * | 2015-08-28 | 2017-03-08 | 南京理工大学 | 一种合成喹唑酮的方法 |
| CN109879820B (zh) * | 2019-02-26 | 2022-07-19 | 扬州大学 | 一种喹唑啉酮杂环化合物的合成方法 |
-
2022
- 2022-10-06 CN CN202280080629.4A patent/CN118354770A/zh active Pending
- 2022-10-06 JP JP2024521052A patent/JP2024538721A/ja active Pending
- 2022-10-06 AU AU2022361421A patent/AU2022361421A1/en active Pending
- 2022-10-06 CA CA3233822A patent/CA3233822A1/en active Pending
- 2022-10-06 WO PCT/US2022/045904 patent/WO2023059802A1/en not_active Ceased
- 2022-10-06 EP EP22879291.7A patent/EP4412605A4/en active Pending
- 2022-10-06 US US18/699,103 patent/US20240398821A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024538721A (ja) | 2024-10-23 |
| EP4412605A4 (en) | 2025-07-30 |
| CA3233822A1 (en) | 2023-04-13 |
| US20240398821A1 (en) | 2024-12-05 |
| EP4412605A1 (en) | 2024-08-14 |
| AU2022361421A1 (en) | 2024-05-09 |
| WO2023059802A1 (en) | 2023-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2339624C2 (ru) | Производные аминоиндазолов и их применение в качестве ингибиторов киназ | |
| CN102958937B (zh) | 作为磷酸二酯酶抑制剂的苯并二氧杂环戊烯或苯并二氧杂环庚烯杂环化合物 | |
| EP2547676B1 (en) | Modulators of hec1 activity and methods therefor | |
| EP1537087A1 (fr) | Derives de 3-aminoindazole comme inhibiteurs de kinase et compositions pharmaceutiques les renfermant | |
| FR2613934A1 (fr) | Composition pharmaceutique a base de 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1h-imidazol-1-yl) methyl)-4h-carbazol-4-one et de la ranitidine, son procede de fabrication, l'utilisation de ses deux principes actifs pour la fabrication d'un medicament | |
| EA004539B1 (ru) | Комбинационная терапия для лечения резистентной депрессии | |
| WO1993000094A2 (en) | Use of tetrahydrobenzazepine derivatives for the treatment of portal hypertension and migraine | |
| EP2294068B1 (fr) | DERIVES DE 1,3-DIHYDRO-2H-PYRROLO(3,2-b) PYRIDIN-2-ONE, LEUR PREPARATION ET LEURS APPLICATIONS EN THERAPEUTIQUE | |
| JPH11508920A (ja) | 2,7―置換オクタヒドロ―ピロロ[1,2―a]ピラジン誘導体 | |
| CN102869665B (zh) | 苯并氮杂环庚三烯化合物 | |
| EP2735567A1 (en) | Heterocyclic substituted pyrimidine compound | |
| CN112204025B (zh) | 用于治疗疼痛的化合物,包含其的组合物以及使用其的方法 | |
| JP4236407B2 (ja) | 生理活性なゲピロン代謝産物を使用することによって心理的疾患を治療する方法 | |
| US20240398821A1 (en) | Flavonoid derivatives with gabaa receptor activity and methods of use | |
| WO2020123847A1 (en) | Organic compounds | |
| JP3332929B2 (ja) | ある種の架橋4−フェニル−2−アミノメチルイミダゾール:新しいドパミン受容体サブタイプ特異的リガンド | |
| HK40115276A (en) | Flavonoid derivatives with gabaa receptor activity and methods of use | |
| EP1687314B1 (en) | PREPARATION OF 1-AZA-2-OXA-DIBENZO [e,h] AZULENES AND THEIR USE FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | |
| CA2544297A1 (en) | Use of 2-thia-dibenzo[e, h]azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders | |
| NO313286B1 (no) | Guanidinylamino heterocykelforbindelser nyttige som alfa-2 adrenerge reseptoragonister | |
| NO970183L (no) | (1H-Indol-4-yl)-piperidin- eller tetrahydropyridin-etylaminer og -etylkarboksamider | |
| WO2025217596A1 (en) | Substituted 2,3-dihydro-4h-benzo[e][ 1,3] oxazin-4-one compounds and methods of use thereof | |
| AU2006291059A1 (en) | Salicylate and gentisate salts of a piperazine compound | |
| JPH07503240A (ja) | 3‐アリールインドールおよび1‐アリールインダゾール誘導体の精神病の治療のための使用 | |
| WO2021046789A1 (zh) | 吲唑-甲酰胺衍生物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40115276 Country of ref document: HK |